Skip to main content
Banner background

Novartis Oncology Universal Co-pay Program

Patients may be eligible for immediate co-pay cost savings on their next prescription of TABRECTA® (capmatinib) tablets.

  • Eligible patients with private insurance may pay $0 per month
  • Novartis will pay the remaining co-pay, up to $15,000 per calendar year*

Encourage your patients to find out if they are eligible to enroll in the Novartis Oncology Universal Co-pay Program by visiting or calling 1-877-577-7756.

Novartis Universal Co-pay Card

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit or call 1-877-577-7756.

Patient Assistance Now Oncology

Patient Assistance Now Oncology (PANO) is a support center consisting of insurance specialists and case managers who provide access to information regarding an array of services. Consider PANO your first stop for information about Novartis Oncology Patient Support services. Dedicated support specialists help direct callers to the services that best fit their needs.

To learn more, call 1-800-282-7630 or visit

Patient Assistance Now Oncology program

Free Trial Program

With the Free Trial and Access Program, eligible patients can receive a free supply of Novartis medication for a US Food and Drug Administration–approved indication. The supply can be shipped directly to patients so they can start treatment immediately. Program rules may vary by product.

Help your patients apply for this program by submitting the Novartis Service Request Form, available at

Patient Support Resources Brochure PDF

Patient Support Resources Brochure

Learn more about how Novartis can help support your patients with mNSCLC.

Important Safety Information

Interstitial Lung Disease (ILD)/Pneumonitis. ILD/pneumonitis, which can be fatal, occurred in patients treated with TABRECTA. ILD/pneumonitis occurred in 4.8% of patients treated with TABRECTA in the GEOMETRY mono-1 study, with 1.9% of...


TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.